Our results on poorly differentiated sinonasal carcinomas revealed that at least one of the immunotherapeutic biomarkers >10% CD8+ TILs, >5% PD-L1 expression or MSI-positivity occurred in 39% (27/69) of cases. The gene discussed is CD274; the disease is nasal cavity and paranasal sinus carcinoma.